Still Not Sure Re-Importation Is A Good Idea (Yet)

From October 8th Time article on counterfeit drugs:

"The problem is not limited to poor countries, however. When Pfizer recalled 120,000 packs of its cholesterol drug Lipitor in Britain in 2005 after it discovered a counterfeit version, it found that 60% of all the returned packs were fakes. Jacques Franquet, who heads security operations for the French drugmaker Sanofi Aventis, says his teams routinely find fake versions of about 15 of the company's drugs worldwide."


What I can't find out is whether the costs of pedigree programs (e.g., RFID tracking) would be offset by the savings associated with greater re-importation.  I can't imagine that pharmaceutical companies wouldn't find a way to adjust pricing on existing or (most likely) newly launched medications to maintain their revenues.